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Available online xxxxMalnutrition is one of the most common physical manifestations of gastrointestinal (GI) cancers and is often
under-diagnosed and under-treated. Like cancers, malnutrition occurs more commonly in older adults, with po-
tential negative consequences to quality of life, functional status, tolerance to treatment, and prognosis. Nutri-
tional assessment and management require a proactive and systematic, multi-disciplinary approach. Early
assessment, detection, and prompt intervention of cancer–associated malnutrition and cachexia are equally es-
sential to achieve better quality nutritional care for older oncology patients. This article aims to provide an over-
view of the evidence associated with poor nutrition and outcomes in older adults with GI cancers, and
recommends a management approach from a geriatric oncologist's perspective.
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Outcomes in Older Patients With Gastrointestinal Cancers
Almost 30% of cancer incidence and 32% of cancer deathsworldwide
are due to gastrointestinal (GI)malignancies, [1] and both incidence and
mortality rise exponentially with age. The aging process is associated
with sarcopenia, comorbidities with associated loss of functional re-
serve of multiple organ systems, and increased vulnerability to frailty
[2]. Poor nutritional status is a known poor prognostic factor in patients
with malignancies [3,4], causing a significant concern as the risk of
cancer and malnutrition are more common in an older population [5].
In general, approximately 10–20% of cancer deaths can be attributed
to malnutrition rather than the cancer itself [4,6,7]. The French National
Authority for Health definedmalnutrition in older adults as one ormore
of the following: ≥5% weight loss in 1 month or ≥10% in 6 months,
and/or Mini-Nutritional Assessment (MNA) score of b17/30, and/or
serum albumin b35 g/L, and/or body mass index (BMI) of b21 kg/m2
[8]. However, a BMI ≥21 does not exclude the diagnosis of malnutrition,
such as in the case of sarcopenic obesity [9]. Age N70 years and malnu-
trition increase the risk of death 2–2.5 times, respectively [4]. However,
in older patients, it is oftenmore difficult to delineate age-related versus
tumor–related effects on malnutrition. In addition to underrepresenta-
tion in clinical trials and lack of management consensus guidelines,
very few oncologic papers distinguish young from older adults and the
age cut-off values often vary, making their management rather chal-
lenging. This article reviews the current evidence supporting the nega-
tive impact of poor nutrition on the management outcomes of patients
including older adults, with a specific focus on GI cancers.We systemat-
ically identified studies published in English over the last decade on the
nutritional status of older adults with GI cancers through PubMed and
MEDLINE databases, by combining search terms “malnutrition”,
“sarcopenia”, “screening”, “GI cancer”, and “elderly”. Additional articles
were identified from citations in the articles that were evaluated. As the
terminology relating to malnutrition varies, specific terms and defini-
tions used in this manuscript are defined in Table 1.
1.1. Sarcopenia
The aging process is associated with sarcopenia, a gradual and pro-
gressive loss of skeletal muscle mass leading to reduced strength or
physical performance [10] that is commonly seen in sedentary older
adults. Sarcopenia has an estimated prevalence of 30% among adults
N60 years [11] and a decline in muscle mass is expected at a rate of up
to 15% per decade at ≥70 years of age [12]. It accelerates the risk for de-
veloping adverse outcomes such as functional impairment and disabil-
ity [13,14], poor quality of life (QoL) and death [10], and its effect
could be magnified in the presence of malignancy. Regular aerobic and
resistance exercises, along with adequate protein and energy intake
have been shown to help counteract the effects of age-related decline
in musclemass, strength, and function in healthy older adults [15]. Spe-
cific to cancers, sarcopenia has often led to worse outcomes, including




Anorexia Limited food intake from altered CNS appetite signals related to
or functional limitations to food intake (i.e. mucositis, obstructio
Starvation Loss of body fat & non-fat mass caused by poor protein-energy o
Sarcopenia Reduction or loss of skeletal muscle mass and strength with agin
Cancer cachexia Involuntary multifactorial wasting of protein or energy stores an
of fat mass.
Release of pro-inflammatory cytokines results in significant weig
in physical function
CNS = central nervous system.
Please cite this article as: Mislang AR, et al, Nutritional management of o
Geriatric Oncology (SIOG) review paper, J Geriatr Oncol (2018), https://dtoxicities [16,17], the mainstay of treatment for most GI cancers, and a
2-fold increased mortality for patients with colorectal cancer (CRC)
with N5% muscle loss post-chemotherapy [18]. Table 2 summarises
the negative consequences of sarcopenia in GI cancers.
1.2. Cachexia
Cachexia is provisionally defined as ≥5% involuntary weight loss
over 6 months; or BMI b20 and any degree of weight loss ≥ 2%; or
sarcopenia and any degree ofweight loss N2% [19]. Although, such a def-
inition has gained somepopularity among clinicians, it does not account
for the different BMI thresholds between younger and older adults
[20–22]. Moreover, refractory cachexia, a syndrome commonly defined
as irreversible and unresponsive to nutritional interventions [3], may
not always be accurate, as the provision of nutritional support becomes
more sophisticated and specific. For instance, it is now possible to inte-
grate nutritional supplements with anabolic or anti-catabolic agents
[23], to better treat the cachectic status compared to using standard
nutritional support.
Cachexia is commonly associated with inadequate nutrient intake
leading to a general state of deterioration and deconditioning, de-
creased or absent physical activity, and altered metabolism due to a
pathological systemic inflammatory response [24]. This condition can
occur even in the absence of apparent weight loss, or prior to losing
fat mass, and can be exacerbated by cancer therapy [25]. It may also
be obscured by obesity, resulting in under-diagnosis and excessmortal-
ity [25]. The cancer itself and its related treatments often cause taste and
smell alterations, appetite loss, swallowing and absorption disorders,
and enhanced catabolism [19], leading to higher nutritional risk. In the
absence of appropriate intervention, loss of substantial muscle mass is
almost inevitable and will eventually lead to progressive cachexia.
Management is therefore multidimensional, and involves early initia-
tion of nutritional care or support, resistance exercises to prevent mus-
cle atrophy, endurance exercises to counteract fatigue, and treatment of
inflammation-related hypermetabolic state [19] where possible.
1.3. Gastrointestinal Cancers
Nutritional risk, although common in older adults with cancer, is
notably higher in patients with GI malignancies, particularly in the
presence of GI symptoms [26] such as, anorexia, early satiety, nausea,
vomiting, dysphagia, odynophagia, diarrhea, constipation, malabsorp-
tion, and pain. In some patients, unintentional weight loss, mostly
from GI symptoms, is present long before the diagnosis of malignancy
is made. Weight loss at presentation has been associated with reduced
ability to tolerate anti-cancer therapy, increased severe dose-limiting
toxicities, lesser response rates, worse QoL, decline in performance
status, and shorter survival outcomes among patients with locally
advanced or metastatic GI cancers [27]. The prevalence varies
depending on the definition used in the literature and the GI cancer
type – 28–54% in hepatocellular, 39–71% in colorectal, and 56% in pan-
creatic cancers [28].Intervention
disease or its treatment, or from structural
n, altered intestinal transit, etc.)
Pharmacologic agents
r nutrient intake Adequate nutritional support
g, which may lead to functional impairment Physical exercise
High protein and energy diet
d skeletal muscle mass, with or without loss
ht loss, altered body composition, and decline
Physical exercise
High protein and energy diet
Anti-inflammatory agents
Anti-cancer treatment
lder adults with gastrointestinal cancers: An International Society of
oi.org/10.1016/j.jgo.2018.01.003
Table 2












Esophageal or esophagogastric cancer
Anadavadivelan
et al., 2016 [96]





obesity and DLT after cycle 1
CT
n = 72









Increased DLT with sarcopenic
obese (OR 5.54; p = 0.04)










Surgery 65% Worse OS
• Sarcopenia: HR 1.87, p = 0.011
• ≤40 HU muscle attenuation:
HR 1.91, p = 0.019
• FMi: HR 3.47, p = 0.016
Tan et al., 2015 [34] Retrospective data from MDT
Single centre









CT: ECX or CF
49% Sarcopenia
• more common in older patients
(68.6 ± 7 years vs. 63.1 ±
8.3 years)
• higher DLT (54.5% vs. 28.9%;
p = 0.015)
• lower median OS (569 vs.
1013 days); p = 0.04
• no difference in OS in patients with
DLT independent of sarcopenia
Gastric cancer














45% Reduction in lean tissue mass
during neoadjuvant CT (p = 0.001)
Poor OS in patients with low preop
skeletal muscle index (HR 1.91,
p = 0.019)





Prevalence of sarcopenia and
association with CT toxicity
and long-term outcomes
n = 48






Age N 65: lower muscle attenuation
DLT: 46%
Sarcopenia:
• Increased CT termination
(OR 4.23, p = 0.05)
Sarcopenic obesity:
• Lower OS (6 vs. 25 months,
p = 0)
Qiu et al., 2015 [35] Prospective data from NRS
Single centre
Prevalence and prognostic
value of nutrition risk (all
stages) and nutritional




CT 50.7 (NRS ≥3) • Longer median OS for NRS b3:
31.9 vs. 25.7 months, p b 0.001
• NRS shift with nutritional
support: 30.3%
• Improved median survival with
NRS shift: 14.3 vs. 9.6 months;
p = 0.001
Seo et al., 2016
[100]









Adjuvant CT 59% • LBM and low albumin increased
risk for grade 3 or 4 hematological
toxicities
• Age was an independent risk factor














Age ≥ 70: 41%






Significantly poorer DFS in patients
≥70 with sarcopenia
• Sarcopenia
• Stage III or IV
Blood transfusion













Liver surgery 54% Sarcopenia:
• more common in older patients
(p = 0.013)
• 71.2 vs. 40% disease recurrence
(p = 0.002)
• 34 vs. 14% deaths at
21.23 months median follow-up
• shorter median PFS (10.1 vs.
34.23 months, p b 0.001)
• shorter median OS (52.3 vs.
70.3 months, p = 0.015)
• poorer OS (HR = 3.19, p= 0.013)
(continued on next page)
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Aaldriks et al., 2013
[38]
Prospective analysis of patient
records
Multicentre
GA to predict tolerance &
feasibility of treatment with












• Adjuvant CT: 20%
• Palliative CT: 33%
Mortality (15 months median
follow-up) among patients
receiving palliative CT
• 2.76-fold risk in MNA b23.5
(p b 0.001)
• 2.72-fold risk in GFI frail
Ali et al., 2016 [103] Prospective data from
physician's notes
Multicentre
Toxicity associated with LBM
during first 4 cycles









40% Dose ≥3.55 mg oxaliplatin/kg ↑ risk
for DLT
25% of DLT was due to neuropathy
Barret et al., 2014
[33]
Prospective, cross-sectional
study based on patient records
Multicentre











71% Sarcopenia was significantly
associated with grade 3 or 4
toxicities (OR 13.55; p = 0.043)





Effect of decreased muscle










BMI ≥ 25: 19%
1 SD decrement in PI was associated
with increased in all grade 3–4
toxicities (OR 1.56) and overall
mortality (OR 1.85)
Higher mortality with:
• age ≥60 (HR 2.94; p = 0.028)






Prognostic value of skeletal
muscle mass pre-CT and rate







1st line CT ±
targeted
therapy
20% Median follow-up, months
PFS: 8.1
OS: 23.2
Skeletal muscle loss N5% post-CT
was significantly associated with
poorer PFS and OS
Prado et al., 2007
[16]
Prospective data from patient
records
Single centre











– 20 mg 5FU/kg LBM is a significant
predictor of overall toxicity (OR
16.75; p = 0.013)
Pancreatic cancer











Adjuvant CT – Overall complication rate: 49%
• N68 years: 53%
TTA: 60 days
Overall adjuvant therapy rate: 54.2%
• N68 years: 39.7%
Median OS: 18.1 months
• ≤68 vs. N68 years: 20 vs.
15 months (p b 0.001)
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impairments in GI cancers with negative outcomes as shown in Table 2.
Nutritional status screening of 1453 patients with cancer (median age
64, range 55–71, 64% had GI cancers), in the outpatient setting using
the Nutritional Risk Score (NRS-2002) of ≥3 as “at-risk”, reported a
22% high nutritional-risk rate among patients with GI cancer, particu-
larly in the presence of worsening performance status, fatigue and an-
orexia symptoms [29]. In a cross-sectional study of 313 patients
(mean age 63 years) with GI cancers, the malnutrition rate was 52%,
where 25% was severe and underestimated by the treating physicians
[30]. Among patients aged ≥70 years (30%), 39% had moderate and
18%had severemalnutrition [30]. Factors associatedwith severemalnu-
trition include performance status, ≥3 prior lines of treatment, pancre-
atic, and gastric cancers [30]. Malnutrition has also led to increased
incidence of perioperative complications (i.e. infections, delayed
wound healing, wound dehiscence, etc.), poorer tolerance or aug-
mented toxicities to treatment, altered QoL, higher hospital costs, and
mortality [31]. In a cohort study associating sarcopenia with postopera-
tive morbidity and mortality after CRC surgery (n = 310), 51.3% of pa-
tients were aged N70 years; age was an independent predictor ofPlease cite this article as: Mislang AR, et al, Nutritional management of o
Geriatric Oncology (SIOG) review paper, J Geriatr Oncol (2018), https://dmortality, and sarcopenia was associated with a higher 30-day or in-
hospital mortality (8.8% vs. 0.7%) [32]. A combination of instruments
assessing function, nutrition, frailty, and sarcopenia can accurately
predict post-operative sepsis [32]. In a multicentre study including
51 metastatic CRC patients (median age 65 years), sarcopenia was
associated with grade 3–4 chemotherapy toxicities (odds ratio, OR
13.55, p= 0.043) [33]. Similarly, sarcopenia was a significant predictor
of dose limiting toxicity in patients with esophago-gastric cancer (n =
89, median age 65.8 years) receiving neoadjuvant chemotherapy
(OR 2.95; 95% confidence interval, CI 1.23–7.09; p = 0.015) [34],
while NRS-2002 ≥3 was an independent adverse prognostic factor in
830 patients with gastric cancer (48% aged ≥70 years), where the me-
dian survival for NRS-2002 b3 was 31.9 months vs. 25.7 months for
NRS-2002 ≥3 (p b 0.001) [35].
Older patients on chemotherapy who are “at risk” of malnutrition
according to the MNA have a 2-fold increase in 1-year mortality [36].
Likewise, a higher 1-year mortality (OR 2.77) was noted in malnour-
ished older (≥70 years) patients treated with first-line chemotherapy
[37]. In a prospective study of 143 patients aged ≥70 years with




Tool Variables Abnormal score Intervention
Malnutrition Screening
Tool [47]


















A. Has food intake declined over the past 3 months due to loss of










B. Weight loss during the last 3 months
N3 kg (6.6 lb) 0
Does not know 1
1–3 kg (2.2–6.6 lb) 2
None 3
C. Mobility
Bed or chair bound 0
Out of bed or chair 1
Goes out 2










1. Body mass index (BMI),
weight in kg/height in m2
Less than 19 0
19–less than 21 1
21–less than 23 2
23 or greater 3





Part 1. Initial screening
Yes or no BMI b 20.5
Weight loss in 3 months
Reduced dietary intake in the last week
Severely ill
If the answer is yes to
any questions
Proceed to Part 2
If the answer is no to all
the questions
Re-screen patient at weekly intervals
If the patient is at risk, e.g. scheduled
for a major operation, consider a
preventative nutritional care plan
Part 2. Final screening
Impaired nutritional status Add total score:
0 Absent Normal ≥3 At risk: initiate nutritional care plan
1 Mild Weight loss (WL) N5% in 3 months or food
intake (FI) b50–75% of normal requirement in
preceding week
2 Moderate WL N5% in 2 months or BMI 18.5–20.5 +
impaired general condition or FI 25–60% of
normal requirement in preceding week
3 Severe WL N5% in 1 month (N15% in 3 months) or BMI
b18.5 + impaired general condition or FI 0–25%
of normal requirement in preceding week
Severity of disease
0 Absent Normal b3 Re-screen patient at weekly intervals
If the patient is at risk, e.g. scheduled
for a major operation, consider a
preventative nutritional care plan
1 Mild Hip fracture; acute complications of chronic
disease; cirrhosis; COPD; diabetes;
hemodialysis; oncology
2 Moderate Major abdominal surgery; stroke; severe
pneumonia; hematologic malignancy
3 Severe Head injury; bone marrow transplant; ICU
(APACHE N 10)
Age if ≥70 years: add 1 to total score
(continued on next page)
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Table 3 (continued)




5 steps to measure: 4. Add scores to












N20 (N30 obese) 0
18.5–20 1
b18.5 2
2. Unplanned weight loss in past 3–6 months
(%) Score 1 Medium Observe
Document dietary intake for 3 days




Community: every 2–3 months
If inadequate: clinical concern – follow
local policy, set goals, improve and
increase overall nutritional intake,




3. Effect of acute disease
Acutely ill, presence or
probability of no nutritional
intake for N5 days
Score ≥2 High Treat*
Refer to dietician, nutritional support
team, or implement local policy
Set goals, improve and increase
nutritional intake





*Unless no benefit is expected from nutritional support, e.g. imminent death
All risk categories:
• Treat underlying condition and provide help and advice on food choices, eating, drinking when necessary
• Record malnutrition risk category
• Record need for special diets and follow local policy
Re-assess subjects identified at risk as they move through care settings
6 A.R. Mislang et al. / Journal of Geriatric Oncology xxx (2018) xxx–xxxpatients receiving palliative chemotherapy (HR 2.76, 95% CI 1.60–4.77;
p b 0.001) but also predicted for less tolerance to chemotherapy (p =
0.008) [38]. Cachexia was associated with poorer survival and perfor-
mance status in pancreatic cancer, independent of tumor size and met-
astatic load [39]. Interestingly, sarcopenia alone was not predictive of
decreased survival in a systematic reviewof pancreatic cancer [40]. A re-
cent systematic review andmeta-analysis (37 studies, 56% with GI can-
cers) of the prognostic value of low skeletal muscle index obtained from
CT screening on any solid tumors at various stages demonstrated that
sarcopenia was associated with worse cancer-specific and disease-free
survival [41].
2. Management Approach From a Geriatric Oncologist's Perspective
Weight loss of as little as 5% of bodyweight has been linked to lower
survival and treatment response in patients with cancer [42]. For pa-
tients with colon, gastric, and pancreatic cancers, survival improvement
without weight loss was 51%, 33%, and 14%, respectively relative to sur-
vival with weight loss [42]. In addition, poor performance status has
been directly correlated with weight loss, suggesting that muscle loss
may impact the level of activity [42]. Therefore, it is recommended to
evaluate the nutritional status of all patients undergoing oncological
treatment [31] from the time of cancer diagnosis and repeated as clini-
cally indicated for inadequate nutritional intake, weight loss, and low
BMI, and to assess for treatable nutrition impact symptoms and meta-
bolic derangements if found to be “at risk” [43]. Evaluation could be as
simple as serial measurement of body weight, or by using nutritional
screening tools, which are quick and easily completed by any health
staff, or with a more exhaustive nutritional assessment, performed by
trained personnel. Such evaluation may be particularly more relevantPlease cite this article as: Mislang AR, et al, Nutritional management of o
Geriatric Oncology (SIOG) review paper, J Geriatr Oncol (2018), https://dto perform in older patients with cancer, as nutritional impairments
are more prevalent, yet easily overlooked without proper assessment
[44,45]. As the process of aging occurs at a heterogeneous pace, the In-
ternational Society of Geriatric Oncology (SIOG) recommends that all
older patients with cancer, especially those considered for anticancer
treatment, undergo a comprehensive geriatric assessment (CGA) [46],
which includes the evaluation of comorbidity, function, nutrition, psy-
chosocial status, and presence of geriatric syndromes, as these provide
multidimensional information on the patients' over-all health status
that may be predictive of mortality and treatment tolerance.
2.1. Nutritional Assessment Tools in Older Adults With GI Cancers
Much information can be gleaned from a full nutritional assessment,
but as with any comprehensive assessment tool, it is time-consuming
and requires specialized nutritional expertise, hence it may be impracti-
cal to use in all patients in a busy oncology clinic. Screening tools are
more useful in this setting and only malnourished patients and those
at risk of malnutrition on screening are referred for a full nutritional as-
sessment and intervention. Validated nutritional screening tools, such
as theMalnutrition Screening Tool (MST) [47], theMini-Nutritional As-
sessment Short Form Revised (MNA-SF) [48], the Nutrition Risk Screen-
ing (NRS-2002) [49], and the Malnutrition Universal Screening Tool
(MUST) [50] may be used in older oncology patients, though these
screening tools have not been evaluated specifically for older adults
with GI malignancies. Table 3 summarises the variables assessed, cut-
off values and proposed interventions in these screening tools. There re-
mains no gold standard for nutritional screening and which cut-off
values to use to initiate further assessment, as none of these tools
were designed specifically for diagnostic, prognostic, or interventionallder adults with gastrointestinal cancers: An International Society of
oi.org/10.1016/j.jgo.2018.01.003
7A.R. Mislang et al. / Journal of Geriatric Oncology xxx (2018) xxx–xxxpurposes. Despite the lack of expert consensus onwhich tool to use, par-
ticularly in older patients with cancer, it is clear that screeningwith any
of the validated tools mentioned, at the very least, should be performed
at the time of diagnosis, on admission to hospitals or care homes, during
clinic follow-ups, and at regular intervals depending on clinical status
[51]. Selection of the most appropriate screening tool is based on set-
ting, familiarity, and practicality [52].
A more specific assessment, such as the MNA, should follow an ab-
normal screening test to detect which patients might benefit from ap-
propriately designed interventions [43]. The MNA is a well-established
and validated nutritional assessment tool in older adults, consisting of
18 items grouped in 4 headings: anthropometric measurements (BMI,
weight loss, arm and calf circumferences), general assessment (lifestyle,
medication, mobility, and presence of depression or dementia), short
dietary assessment (number of meals, food, and fluid intake, and feed-
ing autonomy), and subjective assessment (self-perception of health
and nutrition) [53]. The maximum score is 30, with threshold values
of ≥24 for well-nourished, 17–23.5 for at-risk, and b17 for malnour-
ished. The sensitivity, specificity, and positive predictive values accord-
ing to the clinical statuswere 96%, 98%, and 97%, respectively [54]. It has
been correlated with cancer cachexia features [55] and was one of the
independent predictors for chemotherapy toxicity [56] and early
death [37,57,58].
More recently, other assessment tools have been studied using scor-
ing systems.Martin et al. developed a cancerweight loss grading system
incorporating%weight loss and BMI that predicted nearly a 5-fold differ-
ence in median survival between grades 0 (least risk) and 4 (highest
risk), independent of cancer site, stage, and performance status [59].
The Patient- and Nutrition-Derived Outcome Risk Assessment Score
(PANDORA) is a simple risk scoring system that includes age, BMI, mo-
bility, nutrient intake, main patient group, cancer, and fluid status, and
has been validated to predict 30-day hospital mortality [60]. SpecificPatient with activ
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Geriatric Oncology (SIOG) review paper, J Geriatr Oncol (2018), https://doto older patients, a nomogram was developed based on CGA factors in
older patients with cancer, showing that advanced stage, anemia, de-
pression, and poor ECOG performance status were independently pre-
dictive of moderate to high-risk of malnutrition [61]. However, use of
the scoring system is yet to be validated in clinical practice. The lack of
a gold standard for both screening and full nutritional assessment
tools highlights the dearth of research focusing on validated tools to
measure malnutrition.
2.2. Role of Nutritional, Pharmacologic & Physical Intervention in Older
Adults With GI Cancers
An oncologist is expected to know about patient-, disease-, and
treatment-related factors, and therefore has the critical responsibility
of identifying patientswhowill potentially benefit fromnutritional sup-
port and strategies, including knowing when to refer to dieticians and
integrate the nutritional plan within the oncologic regimen [62]. Al-
though it is clear that a specific intervention is needed to counteract
and manage the deleterious effects of malnutrition, the efficacy and
choice of interventional strategies remain contentious, and evidence
for nutritional management specific to older patients with GI cancers
is lacking. In addition to aging heterogeneity, the patient's nutritional
needs vary according to disease site, cancer stage, disease burden, and
comorbidities that may limit treatment generalization. Algorithms for
managing nutritional needs of older patients with cancer with GI can-
cers are illustrated in Figs. 1 and 2, which may be used as a guide for
the treating oncologist.
2.2.1. Nutritional Intervention
Nutritional counselling, which includes dietary history, diagnosis,
and therapy, is recommended tomalnourished patients with GI cancers
requiring chemotherapy [63], and is usually performed by trainede gastrointestinal cancer
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Fig. 2. Strategies for nutritional approach in a malnourished GI cancer patient.
8 A.R. Mislang et al. / Journal of Geriatric Oncology xxx (2018) xxx–xxxdieticians [43]. Individualized dietary counselling of patients receiving
chemotherapy and/or radiotherapy for esophageal or gastric cancers
has been associated with improved weight maintenance, energy- and
protein-intake without any significant effects on QoL, treatment-
related toxicities, or prevalence of micronutrient deficiencies [64]. In
contrast, a proportional improvement of QoL with adequate nutritional
status was observed among patients with CRC receiving radiotherapy
[65]. Notably, dietary counselling is an individualized, time-consuming
process, which often fails when used in already severely anorectic pa-
tients, although it appears effective in patients with digestive problems
caused by radiation or chemotherapy [66]. The effect of dietary inter-
ventions on QoL, based on two systematic reviews and meta-analyses
[67,68], remains inconclusive, particularly among patients receiving
chemotherapy.Moreover, no trials have shown any benefit onmortality
[68–70] and similar results were found in older populations with can-
cers [71]. As some nutritional interventions may not always be feasible,
particularly in institutions not equippedwith specific “nutritional units”
to accommodate a large number of patients needing intervention, it is
critical to personalize and tailor interventions to each institution's avail-
able resources (Fig. 1).
Although the best way to maintain or increase energy- and protein-
intake is with normal food, it is often difficult and nutritional supple-
ments are often required. Specific to GI cancers, where problems with
dysgeusia, early satiety, nausea, vomiting, or compromised gastric or in-
testinal transit are more prevalent, the utility of an oral approach may
be limited. If oral intake is deemed inadequate or impossible, either
due to the disease or treatment, then supportive feeding, via enteral
or parenteral feeding, may be considered (Fig. 2), taking into account
the goal of treatment (curative vs. palliative), disease trajectory, esti-
mated life expectancy, and with anticipated benefits weighed against
the potential risks, burdens, and costs. Enteral feeding (oral supple-
ments ± intensive counselling or tube feeding) may be as efficient as
parenteral feeding, particularly if intestinal functions are preservedPlease cite this article as: Mislang AR, et al, Nutritional management of o
Geriatric Oncology (SIOG) review paper, J Geriatr Oncol (2018), https://d[72], and provides the added benefit of maintaining the gut barrier,
fewer infectious complications, and lower costs [43]. The European
Society for Clinical Nutrition and Metabolism (ESPEN) guidelines on
enteral nutrition in the older population recommend the use of
gastrostomy for long-term (≥4 weeks) nutritional support over naso-
gastric tubes due to fewer treatment failures, better nutritional status,
and convenience to the patient [73]. However, there is no significant dif-
ference in the clinical benefit between nasogastric and gastrostomy
feeding [74] in terms of infection rate and survival outcomes in a sys-
tematic reviewof studies conducted in patientswithhead andneck can-
cers [75]. The ESPEN recommends that nutritional therapy should be
started if malnutrition already exists or if it is anticipated that the pa-
tient will not be able to eat for N7 days [43].
If enteral nutrition is not feasible, contraindicated, or not tolerable in
malnourished cancer patients, then short-term parenteral nutrition
may be considered, particularly in patients with acute GI complications
from surgery, chemotherapy and/or radiotherapy (e.g. severe radiation
enteritis or severe malabsorption) [76]. This decision must be balanced
against a realistic outlook for recovery [77] and prognosis. Of note, the
risk of developing refeeding syndrome increases with the degree of
nutritional depletion and must be monitored and managed pre-
emptively [78].
Patients with rapidly progressive disease with poor performance
status and limited life expectancy are less likely to benefit from aggres-
sive nutritional interventions. However, trial of oral or less invasive nu-
tritional support may be offered to provide symptomatic or comfort
care [43]. Long-term (home) parenteral nutrition (HPN)may be consid-
ered in patients with subacute or chronic radiation enteropathy, or as a
palliative nutritional support in hypophagic or (sub)obstructed patients
with acceptable performance status, or in patients who are expected to
die sooner from starvation rather than cancer [76]. Among 414 cachectic
(sub)obstructed, incurable patients (41% were ≥65 years and 56% had
GI cancers), HPN has been associated with a longer 3- and 6-monthlder adults with gastrointestinal cancers: An International Society of
oi.org/10.1016/j.jgo.2018.01.003
9A.R. Mislang et al. / Journal of Geriatric Oncology xxx (2018) xxx–xxxsurvival (than is expected with total macronutrient deprivation) and
varies considerably with Karnofsky performance status and Glasgow
prognostic score [79]. Complications from long-term enteral (tube
obstruction or displacement, diarrhea, or constipation) or parenteral
(infections, thrombosis, or obstruction) nutrition are similar regardless
of age [80], although a higher risk for central catheter vascular erosion
(p = 0.009) [81] was seen in older compared to younger patients.
2.2.2. Pharmacologic Intervention
Supportive drugs, such as antiemetics to relieve nausea, analgesics to
relieve pain associated with swallowing or other GI activity, motility
agents to treat constipation or diarrhea, prokinetics to improve intesti-
nal transit, and pharmaconutrients such as ω−3 fatty acids to improve
appetite and body weight, may be used to target the main pathogenic
mechanisms of cancer cachexia [43]. Corticosteroidsmay increase appe-
tite, control pain, alleviate nausea or vomiting, and improveQoL [82] but
may only be used for a restricted period of time (1–3 weeks), due to
early loss of efficacy [83], and the side-effects with long-term use may
bemore problematic in the elderly where sarcopenia, insulin resistance,
infections, or delirium are more prevalent. Thus, corticosteroids may be
more useful in the palliative setting among patients with limited life ex-
pectancy [84]. There is insufficient evidence to recommend any particu-
lar corticosteroid drug over another, or recommend a dosing regimen
[84]. Progestins (megestrol acetate and medroxyprogesterone acetate)
increase appetite, caloric intake and body weight but not fat-free
mass, with minimal effect on QoL [82] and higher rates of edema,
thromboembolism, and deaths [82]. ω−3 fatty acids (fish oil) improve
appetite, oral intake, lean body mass and body weight in patients
with advanced cancer and at risk of malnutrition [3]. A non-significant
delay in time to tumor progression was noted when supplemental
2 g/day of fish oil was given to patients with advanced CRC in the
first 9weeks of chemotherapy [85]. Less chemotherapy-induced stoma-
titis and diarrhea, and more hepatoprotective effects were noted with
ω−3-rich enteral nutrition support than with theω−3-poor formula-
tion, among 61 patients (mean age 64.5± 8.4 years)who received neo-
adjuvant chemotherapy for esophageal cancer. Branched-chain amino
acids, especially leucine, promote muscle protein synthesis in older
adults, provided that renal function is not severely impaired [15].
There are insufficient consistent clinical data to recommend use of can-
nabinoids to improve appetite [86,87] or the use of NSAIDs to increase
body weight [88], amino acids to improve fat-free mass [89], or andro-
genic steroids to boost muscle mass [90].
2.2.3. Physical Intervention
There is a strong association between physical activities and preser-
vation of body composition among highly active older adults [91].
Physical activities in patients with cancer have been associatedwith im-
proved aerobic fitness, muscle strength, health-related QoL, and psy-
chological benefits [92,93]. However, most of these studies were
conducted in women with early stage breast cancers who clearly have
different demands compared to patients with GI cancers. Combinations
of resistance exercises and aerobic muscle training may provide signifi-
cant benefit in physical performance [94], at least among patients who
are not limited by extreme fatigue. The ESPEN recommends all older
people to undertake daily physical activities (resistance training, aero-
bic exercise) for as long as possible [15]. However, data specific to
older patients with GI cancer are lacking. Physical activity may amelio-
rate the age-related decrease in energy expenditure, and individualized
physical interventions to reduce inactivity and avoidance of a sedentary
lifestyle are essential [43].
3. Palliative and Ethical Considerations
As with any older patients with malignancy, nutritional treatment
goalsmust be individualizedwithin the context of the disease trajectory
or prognosis, overall health status or life expectancy, and patientPlease cite this article as: Mislang AR, et al, Nutritional management of o
Geriatric Oncology (SIOG) review paper, J Geriatr Oncol (2018), https://dopreferences. Timely palliative care and social work referralsmay be nec-
essary to provide a holistic psycho-emotional assessment and support
to address the impact of sarcopenia or cancer cachexia. Discussion
with patients (and caregivers) regarding artificial nutritional andhydra-
tion must be done as early as possible, particularly in the setting of a
pre-terminal stage when such interventions are futile. Nevertheless, a
short trial with a pre-specified endpoint may be considered in select
cases of prognostic uncertainty, with the understanding that the inter-
vention will be discontinued if the patient derives no benefit or deteri-
orates with the intervention [95]. The decision to initiate, continue or
withhold, or withdraw nutritional interventions in imminently dying
patients is often challenging, and a rather controversial topic riddled
with social, cultural, economic, and emotional implications, and is be-
yond the scope of this paper.
4. Conclusion
Nutritional risks are common inGImalignancies and in older patients
with cancer. Inadequate nutrient intake often leads to deterioration of
general state and deconditioning. Malnutrition in older patients with
cancer is associated with poorer health outcomes, worse prognosis,
and less tolerance to treatment. Screening for nutritional risks is essen-
tial upon diagnosis followed by further assessment if found at risk or ab-
normal, with regular monitoring thereafter. Interventions, including
physical activities, dietary counselling, supplemental nutrition, and en-
teral or parenteral feedings should be considered in order to improve
function, nutritional status, and possibly QoL. Management relies on a
multidisciplinary effort between the oncologists, other health care pro-
fessionals, and caregivers. In the absence of a well-defined consensus
formanaging the nutritional needs of older patientswithGI cancers, per-
sonalized treatment with the use of good clinical judgement is crucial.
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